CIRCA-MED WP1 & WP3 - Circadian Rhythms in ICU Patients
Retrospective Characterization of Circadian Rhythms Using Vital Signs and Other Routine Data From Patients in the Intensive Care Unit
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
-
Berlin, Tyskland, 10117
- Institute of Medical Informatics, Charite University, Berlin
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
Primary Retrospective Cohort:
- Admitted to and treated in a participating Intensive Care Unit (ICU) between 2017 and 2024
- Minimum ICU length of stay of 3 days (≥ 72 hours)
- Age ≥ 18 years at the time of ICU admission
- All genders (male, female, diverse)
Cohorts from previous studies:
- Prior enrollment in one of the designated parent study protocols
- Availability of supplementary biological or metabolic data (e.g., clock gene expression, melatonin levels) suitable for exploratory association analyses
Exclusion Criteria:
- None
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
All retrospective patients between 2017 and 2024
Relates to retrospective data from all patients who spent at least three days in participating intensive care units at Charite University, Berlin, Germany between 2017 and 2024
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
|
|
Pa-COVID (DRKS00021688)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
SeptiCLOCK (NCT02044575)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
VITALITY (NCT02143661)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
TRG-N (ISRCTN77569430)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
These exposures represent metabolic consequences of critical illness: insulin sensitivity, muscle atrophy, and critical illness myopathy or ICU-acquired weakness.
|
|
CIPCIM2 (ISRCTN19392591)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
These exposures represent metabolic consequences of critical illness: insulin sensitivity, muscle atrophy, and critical illness myopathy or ICU-acquired weakness.
|
|
CGM (NCT02296372)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
|
|
HELIA-ICU (NCT05556811)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
PICS-Analyse (EA1/229/24)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Characterization of circadian periodicities and classification of time-varying patterns based on routine clinical data
Tidsramme: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Assessment of periodicities and time-varying patterns in routine clinical parameters, including heart rate, body temperature, blood pressure, blood glucose, and insulin levels.
Time-series analysis will be conducted to extract continuous metrics (amplitude, period, and phase).
Based on these metrics, patients will be classified into distinct categorical groups according to their periodic oscillation profiles.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Association between circadian rhythm category and clinical severity scores
Tidsramme: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Relationship between circadian rhythm classification and illness severity (e.g., SOFA score), sedation level, and use of organ support therapies.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
|
Association between circadian rhythm disruption and critical illness-related conditions
Tidsramme: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks), and post-ICU period (up to 3 and 6 months).
|
Presence of delirium, ICU-acquired muscle weakness/critical illness myopathy, and PICS in relation to circadian rhythm category.
Delirium will be measured with the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) binary scale (Positive/Negative).
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks), and post-ICU period (up to 3 and 6 months).
|
|
Association between time-varying clinical patterns and external biological markers (from other studies)
Tidsramme: Depending on individual study protocols, from ICU admission through 24 months post-discharge. Sampled daily to weekly during the ICU stay, followed by post-discharge examinations conducted at variable monthly intervals (a maximum of 5 visits).
|
Exploratory associations between oscillatory trends in routine clinical data and biological markers reported in other studies, such as clock gene expression, melatonin levels, insulin sensitivity, muscle atrophy, and critical illness myopathy.
Only associations will be evaluated.
|
Depending on individual study protocols, from ICU admission through 24 months post-discharge. Sampled daily to weekly during the ICU stay, followed by post-discharge examinations conducted at variable monthly intervals (a maximum of 5 visits).
|
|
Feasibility and Data Infrastructure for Real-Time Circadian Visualization (Chrono-Apps)
Tidsramme: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Evaluation of the technical feasibility and data integration requirements for generating real-time circadian visualizations within the Patient Data Management System (PDMS).
Feasibility will be assessed based on data completeness, sampling frequency compliance, latency of time-series data streaming from routine ICU monitors, and system stability required to display continuous circadian profiles via Chrono-Apps.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
|
Performance of Algorithm-Based Light Therapy Recommendations
Tidsramme: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Retrospective evaluation of the accuracy and stability of the time-series analysis designed to estimate circadian phase of routine clinical data (vital signs) and generate individualized lighting schedules.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- EA1/284/22
- 541063275 - TRR 418 (Andet bevillings-/finansieringsnummer: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .